This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
Potential novel approach for promoting remyelination and inhibiting autoimmune activation identified
Biogen Idec announced results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach in the treatment of multiple sclerosis by blocking autoimmune response while promoting remyelination. Data from in vitro and in vivo models were published online and will be published in the July print issue of Nature Medicine.
"Our approach to finding new treatments for this complex disease looks beyond known pathways affected by current MS treatments," said Sha Mi, Ph.D., distinguished investigator, neurobiology research, Biogen Idec. "Our in vivo and in vitro studies demonstrate that inhibiting or blocking DR6 function results in robust axonal remyelination. These data provide strong evidence that this targeted approach warrants further research and ultimately may lead to an important new way of treating demyelinating diseases, including MS."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1845